GHK and DNA: resetting the human genome to health — VialBase Research

Summary

This study used the Broad Institute Connectivity Map (CMap) database to identify GHK as a molecule capable of reversing disease-associated gene expression signatures. Specifically, GHK was shown to reverse the gene expression pattern associated with COPD/emphysema and aggressive cancer, suggesting it could “reset” diseased tissue gene expression toward a healthier state.

Key Findings

• GHK reverses 70% of genes overexpressed in COPD lung tissue
• CMap analysis shows GHK can reverse gene expression signatures of aggressive metastatic cancer
• Upregulates tissue remodeling genes (TGF-β superfamily, collagen, elastin)
• Suppresses genes associated with tissue destruction and inflammation
• Gene expression effects are broader than expected from a simple tripeptide
• Proposed mechanism: epigenetic modulation and transcription factor regulation

Methodology

Bioinformatic analysis using the Broad Institute Connectivity Map (CMap) database. Disease-associated gene expression signatures (COPD, cancer) compared against GHK-induced gene expression changes in human cell lines. Overlap analysis to identify genes modulated by GHK.

Limitations

• Entirely computational/bioinformatic — no direct clinical validation
• CMap database uses cell line data that may not reflect in-vivo effects
• Gene expression changes do not guarantee functional/clinical outcomes
• COPD and cancer claims require direct preclinical and clinical testing
• Author conflict of interest (GHK-Cu patent holder)

Relevance to Content

The “resetting gene expression to health” narrative is powerful for content. Useful for positioning GHK-Cu beyond skin/cosmetic applications into systemic health. The COPD angle opens respiratory health content possibilities. Important to note the computational nature of evidence — this is hypothesis-generating, not clinical proof.

See Also

• Parent compound: GHK-Cu
• GHK